@ellaf_altamimi's tirzepatide claims, fact-checked

What did @ellaf_altamimi actually say?

Not much, honestly. The creator came home from work, opened a package from Simple Peptide, and announced they were "adding peptides" to what sounds like a weight-loss or wellness routine. They mentioned receiving "cuz up a tide" (almost certainly semaglutide, a GLP-1 receptor agonist) along with bacteriostatic water for reconstitution. That is the entire content of the video.

There are no specific dosage claims, no mechanism explanations, and no before-and-after results presented. What the video does do is normalize buying injectable GLP-1 medications from a vendor operating in the peptide grey market, which is a meaningful public health signal even if the creator never spells that out. The hashtags say the quiet part loud: #glp1medication, #trizepitide, #greymarket.

Does the science back this up?

Semaglutide itself has strong clinical backing. The question here is not whether the molecule works, it is whether what arrived in that box is actually semaglutide, at what purity, and whether it is safe to self-administer without clinical oversight.

The FDA-approved versions of semaglutide (Ozempic, Wegovy) have been studied in large randomized controlled trials. The STEP 1 trial (Wilding et al., 2021, New England Journal of Medicine) showed 14.9% mean body weight reduction over 68 weeks in adults with obesity. Tirzepatide, a dual GIP/GLP-1 agonist, showed up to 20.9% weight reduction in the SURMOUNT-1 trial (Jastreboff et al., 2022, New England Journal of Medicine). These results are for pharmaceutical-grade compounds, administered under medical supervision, with known concentration and sterility testing. Peptides sourced from grey-market vendors carry none of those guarantees.

What did they get wrong (or right)?

The creator did not make any explicit false health claims, so there is nothing factually incorrect in the words they said. Credit where it is due: they are not promising miracle results or citing fake studies.

What is concerning is the implicit framing. Buying compounded or raw semaglutide from a peptide vendor and self-injecting it is not the same as a clinically supervised GLP-1 prescription. The FDA issued warnings in 2023 and 2024 about counterfeit and mislabeled semaglutide products circulating in the grey market, including products with incorrect concentrations that led to hospitalizations. The agency found sodium chloride sold as semaglutide and products with 10 times the intended dose. Self-reconstituting a lyophilized powder adds another layer of risk: incorrect dilution can mean dramatically wrong dosing. None of this appeared in the video, which is part of the problem.

What should you actually know?

If you are considering GLP-1 therapy, the sourcing question matters as much as the molecule itself. Here is what the evidence and regulatory record actually say.

• The FDA placed several grey-market semaglutide products on import alert in 2024, citing sterility failures and mislabeling.
• Compounded semaglutide from a licensed 503A or 503B pharmacy is not the same as brand-name Ozempic or Wegovy, and the FDA has been explicit that these are not interchangeable products.
• Self-injection of GLP-1 agonists without medical oversight removes the clinical monitoring that catches side effects like pancreatitis, gastroparesis, and thyroid concerns that were flagged in the original trials.
• Bacteriostatic water reconstitution sounds simple but incorrect concentration calculations are a documented source of accidental overdose in grey-market peptide use.
• Simple Peptide and similar vendors typically sell products labeled "for research use only," a legal disclaimer that does not protect the buyer if the product causes harm.

The bottom line on grey-market GLP-1 sourcing

The creator's excitement is understandable. GLP-1 medications are expensive, hard to access, and produce real results in clinical studies. The grey market exists because legitimate access is broken for many people. That is a real problem. But the solution of buying reconstitutable powder from a peptide vendor and self-injecting it introduces risks that the clinical trials were specifically designed to screen out. If you want GLP-1 therapy, a regulated telehealth provider who requires labs, a prescriber review, and a licensed pharmacy is not bureaucratic friction. It is the part that keeps the dose from being ten times what you intended.